DelveInsight’s, “Becker Muscular Dystrophy Pipeline Insight 2023” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Becker Muscular Dystrophy pipeline landscape. It covers the Becker Muscular pipeline drug profiles, including Becker Muscular clinical trials and nonclinical stage products. It also covers the Becker Muscular therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Becker Muscular Dystrophy Pipeline treatment landscape of the report, click here @ Becker Muscular Dystrophy Pipeline Outlook

 

Key Takeaways from the Becker Muscular Dystrophy Pipeline Report

• DelveInsight’s Becker Muscular Dystrophy Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Becker Muscular Dystrophy.
• The leading Becker Muscular Dystrophy Companies include Italfarmaco, Immunoforge Co., Ltd., Edgewise Therapeutics, Epirium Bio, Ultragenyx, Strykagen, NS Pharma, Nippon Shinyaku, Pfizer, Taiho Pharma, Catabasis Pharmaceuticals, Sarepta Therapeutics Inc, Italfarmaco, Syneos Health, PTC Therapeutics, Santhera Pharmaceuticals, Hoffmann-La Roche, and others
• Promising Becker Muscular Dystrophy Pipeline Therapies include RO7239361, eteplirsen, Idebenone, Ataluren, givinostat, Edasalonexent, TAS-205, Viltolarsen, and others
• In the Becker Muscular Dystrophy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Becker Muscular Dystrophy clinical trials studies, Becker Muscular Dystrophy NDA approvals (if any), and product development activities comprising the technology, Becker Muscular Dystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
• The Becker Muscular Dystrophy companies and academics are working to assess challenges and seek opportunities that could influence Becker Muscular Dystrophy R&D. The Becker Muscular Dystrophy therapies under development are focused on novel approaches to treat/improve Becker Muscular Dystrophy.

 

For further information, refer to the detailed Becker Muscular Dystrophy Unmet Needs, Becker Muscular Dystrophy Market Drivers, and Becker Muscular Dystrophy Market Barriers, click here for Becker Muscular Dystrophy Ongoing Clinical Trial Analysis

 

Becker Muscular Dystrophy Overview

Becker muscular dystrophy (BMD) is an inherited condition that causes progressive weakness and wasting of the skeletal and cardiac (heart) muscles. It primarily affects males. The age of onset and rate of progression can vary. Muscle weakness usually becomes apparent between the ages of 5 and 15. The symptoms of Becker muscular dystrophy (BMD) may begin anywhere from childhood to a person’s early 20s.

 

Request a sample and discover the recent advances in Becker Muscular Dystrophy Ongoing Clinical Trial Analysis and Medications, click here @ Becker Muscular Dystrophy Treatment Landscape

 

Becker Muscular Dystrophy Emerging Drugs

• Givinostat: Italfarmaco

Givinostat (INN) or gavinostat (originally ITF2357) is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Since Givinostat acts on the pathogenetic events downstream of the genetic defects, it is potentially a treatment for the whole DMD and BMD population and to counter the disease pathogenetic events in all muscular districts. The drug is currently being evaluated in Phase II clinical to treat becker muscular dystrophy.

• EDG-5506: Edgewise Therapeutics

Edgewise Therapeutics Continued to advance a Phase I MAD study of EDG-5506, a small molecule drug candidate designed to arrest muscle fiber breakdown in Duchenne and Becker muscular dystrophy (DMD and BMD).

 

Dive deep into rich insights for drugs for Becker Muscular Dystrophy Market Drivers and Becker Muscular Dystrophy Market Barriers, click here @ Becker Muscular Dystrophy Unmet Needs and Analyst Views

 

Becker Muscular Dystrophy Pipeline Therapeutics Assessment

There are approx. 8+ key companies which are developing the therapies for Becker Muscular Dystrophy. The companies which have their Becker Muscular Dystrophy drug candidates in the most advanced stage, i.e. Phase II include, Italfarmaco.

 

Scope of the Becker Muscular Dystrophy Pipeline Report

• Coverage- Global
• Becker Muscular Dystrophy Companies- Italfarmaco, Immunoforge Co., Ltd., Edgewise Therapeutics, Epirium Bio, Ultragenyx, Strykagen, NS Pharma, Nippon Shinyaku, Pfizer, Taiho Pharma, Catabasis Pharmaceuticals, Sarepta Therapeutics Inc, Italfarmaco, Syneos Health, PTC Therapeutics, Santhera Pharmaceuticals, Hoffmann-La Roche, and others
• Becker Muscular Dystrophy Pipeline Therapies- RO7239361, eteplirsen, Idebenone, Ataluren, givinostat, Edasalonexent, TAS-205, Viltolarsen, and others
• Becker Muscular Dystrophy Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Becker Muscular Dystrophy Mergers and acquisitions, Becker Muscular Dystrophy Licensing Activities @ Becker Muscular Dystrophy Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Becker Muscular Dystrophy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Drug Name: Company Name
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Givinostat: Italfarmaco
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. EDG-5506: Edgewise Therapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Becker Muscular Dystrophy Key Companies
17. Becker Muscular Dystrophy Key Products
18. Becker Muscular Dystrophy- Unmet Needs
19. Becker Muscular Dystrophy- Market Drivers and Barriers
20. Becker Muscular Dystrophy- Future Perspectives and Conclusion
21. Becker Muscular Dystrophy Analyst Views
22. Becker Muscular Dystrophy Key Companies
23. Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services